Liquid Biomarkers in Prostate Cancer Diagnosis: Current Status and Emerging Prospects

Area of Science:

• Oncology
• Biomarker Discovery
• Diagnostic Medicine

Background:

• Prostate cancer (PCa) diagnosis faces challenges with conventional methods.
• There is a need for accurate, non-invasive diagnostic tools for timely intervention.
• Current methods can lead to unnecessary biopsies, especially with borderline PSA levels.

Purpose of the Study:

• To critically evaluate liquid biopsy techniques for prostate cancer diagnosis.
• To assess the role of blood- and urine-based biomarkers in overcoming diagnostic limitations.
• To explore emerging biomarkers for personalized PCa management.

Main Methods:

• Review of existing literature on liquid biopsy techniques for PCa.
• Analysis of blood-based biomarkers (e.g., 4Kscore, Prostate Health Index).
• Evaluation of urine-based biomarkers (e.g., PCa antigen 3, SelectMDx, ExoDx Prostate IntelliScore).
• Investigation of novel biomarkers like non-coding RNAs, ctDNA, and PSA glycosylation.

Main Results:

• Blood and urine biomarkers like 4Kscore, Prostate Health Index, and SelectMDx effectively distinguish PCa from benign conditions.
• Urinary biomarker tests have significantly improved risk stratification and reduced unnecessary biopsies.
• Emerging biomarkers provide deeper insights into PCa biology for tailored treatments.

Conclusions:

• Non-invasive liquid biomarkers represent a significant advancement in PCa diagnostics.
• These biomarkers aid in patient stratification, particularly for those with PSA levels between 4-10 ng/mL.
• Liquid biopsies hold promise for minimizing unnecessary procedures and enabling personalized treatment strategies in prostate cancer care.